Question 1

What are the potential side effects of Ifinatamab Deruxtecan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors clinical trial (NCT04145622). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors clinical trial (NCT04145622). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors clinical trial (NCT04145622). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors clinical trial (NCT04145622). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my cancer worsens during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors clinical trial (NCT04145622). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any specific eligibility criteria I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors clinical trial (NCT04145622). Contact the study team or your healthcare provider for specific answers.

What this study is about